Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.72 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.72 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.67 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.61 |
| ▸ | FAAH | O00519 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.51 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15649627 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL1059785 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL15649602 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL23833964 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL8006368 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL25183155 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL542910 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL11676490 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL7325048 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH | |
| SCHEMBL2910119 | 1.00 | PLA2G2A (0.72) | PLA2G2APLA2G5NOD1PLA2G10FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087250-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2021-03-25 | — | — | US | claimed |
| EP-3006045-B3 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | CYPRUMED GMBH (AT) | 2021-03-17 | — | — | EP | claimed |
| EP-3773475-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | Cyprumed GmbH (AT) | 2021-02-17 | — | — | EP | claimed |
| WO-2019193204-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2019-10-10 | — | — | WO | claimed |
| EP-3204045-B1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2018-12-05 | — | — | EP | claimed |
| US-20180280481-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | CYPRUMED GMBH (AT) | 2018-10-04 | — | — | US | claimed |
| WO-2018065634-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE NASAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2018-04-12 | — | — | WO | claimed |
| US-20170304195-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2017-10-26 | — | — | US | claimed |
| EP-3204045-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | Cyprumed GmbH (AT) | 2017-08-16 | — | — | EP | claimed |
| WO-2017060500-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | CYPRUMED GMBH (AT) | 2017-04-13 | — | — | WO | claimed |
| EP-3006045-B1 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | CYPRUMED GMBH (AT) | 2017-04-12 | — | — | EP | claimed |
| WO-2016055550-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | CYPRUMED GMBH (AT) | 2016-04-14 | — | — | WO | claimed |
| EP-3006045-A1 | Pharmaceutical formulations for the oral delivery of peptide or protein drugs | Cyprumed GmbH (AT) | 2016-04-13 | — | — | EP | claimed |
| US-20140056953-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | NOVO NORDISK A/S (DK) | 2014-02-27 | — | — | US | claimed |
| EP-2696847-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | Novo Nordisk A/S (DK) | 2014-02-19 | — | — | EP | claimed |
| WO-2012140155-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | NOVO NORDISK A/S (DK) | 2012-10-18 | — | — | WO | claimed |
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | LE ROUX DANIELLE MARIE (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2026-01-29 | — | — | US | disclosed |
| EP-0393457-A1 | Proteinase inhibitor | SUNTORY LIMITED (JP) | 1990-10-24 | — | — | EP | disclosed |
| US-4442090-A | ACYLATED AMINO ACID | KYOTO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1984-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304195-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE OR PROTEIN DRUGS | SLC30A5, SLC30A6, SON | PLA2G2A 4370/4885PLA2G5 4378/4885NOD1 4020/4885 |
| US-20180280481-A1 | PHARMACEUTICAL FORMULATIONS FOR THE ORAL DELIVERY OF PEPTIDE DRUGS | SLC30A5, SLC39A11, SLC30A6 | PLA2G2A 4464/4885PLA2G5 4186/4885NOD1 3431/4885 |
| US-20210087250-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | VIP, PTMS, VASP | PLA2G2A 565/4885PLA2G5 1839/4885NOD1 4555/4885 |
| US-20140056953-A1 | FATTY ACID ACYLATED AMINO ACIDS FOR ORAL PEPTIDE DELIVERY | SLC27A1, SLC27A2, FABP2 | PLA2G2A 324/4885PLA2G5 1585/4885NOD1 3906/4885 |
| US-20260027062-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | ADM2, TAS2R42, ACP1 | PLA2G2A 2536/4885PLA2G5 3172/4885NOD1 1861/4885 |
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | VIP, GIPR, SLC10A2 | PLA2G2A 1064/4885PLA2G5 2076/4885NOD1 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.